RecruitingPhase 2NCT06584552
LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)
Lactobacillus Paracasei LPB27 On Early Childhood Eczema
Sponsor
The University of New South Wales
Enrollment
100 participants
Start Date
Nov 15, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.
Eligibility
Min Age: 3 MonthsMax Age: 3 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying Lactobacillus Paracasei LPB27 and Maltodextrin for people with allergy and eczema. The study is currently recruiting participants at 1 location. People eligible for this study include aged 3 Months to 3 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTLactobacillus Paracasei LPB27
Probiotic
OTHERMaltodextrin
Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06584552
Related Trials
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT0680726842 locations
Effects of Treatments on Atopic Dermatitis
NCT016316171 location
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT006058781 location
Sodium in the Skin and Atopic Dermatitis
NCT069984462 locations
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
NCT0568915130 locations